Summary
This narrative review examines the mechanistic role of gut microbiota and their metabolites in initiating chronic low-grade inflammation and insulin resistance in obesity and type 2 diabetes. The authors synthesise evidence showing that dysbiosis—alterations in microbial community structure—can trigger inflammatory responses through the host immune system, thereby contributing to metabolic disease pathophysiology. The review emphasises that the interaction between microbial changes, immune activation, and host metabolism represents a critical but incompletely understood pathway in these prevalent metabolic disorders.
UK applicability
The findings are relevant to UK public health policy given the high prevalence of obesity and type 2 diabetes in the UK population. Understanding microbiota-driven inflammation may inform prevention and treatment strategies, including dietary or probiotic interventions, though translation to UK clinical practice requires additional clinical trials in UK populations.
Key measures
Immunological markers of low-grade inflammation; gut microbial composition and metabolite production; indices of insulin resistance; mechanisms linking dysbiosis to metabolic endotoxaemia
Outcomes reported
This review synthesises evidence on how changes in gut microbial composition and their metabolic products may trigger low-grade chronic inflammation and drive insulin resistance in obesity and type 2 diabetes. The authors examine the tripartite interaction between gut microbiota, the host immune system, and metabolism in the pathophysiology of these metabolic disorders.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.